Preclinical pipeline candidates

Program

ARGX-118

Preclinical
Phase 1
Airway Inflammation

Potential in severe airway inflammation indications

 

Externally Sponsored Research

We believe in accelerating discovery processes to bring solutions to patients through innovative and collaborative science-driven research.

Externally Sponsored Research (ESR) can lead to meaningful advances in disease understanding and treatment.

More info

Externally Sponsored Research
 
Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Indication not disclosed

Pipeline

Target
IL-22R

 

LP0145 (ARGX-112) was designed as a SIMPLE Antibody® to block receptor, IL22R. LEO Pharma is evaluating the antibody for atopic dermatitis.

Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Indication not disclosed

Pipeline

Target
MET

AgomAb Therapeutics, a privately held, venture-backed company (www.agomab.com) exclusively licensed the SIMPLE Antibody® technology to generate a set of HGF-mimetic agonists directed at the MET receptor. The lead antibody, AGMB-101 (previously referred to as ARGX-114), has the potential to regenerate damaged tissue in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Indication not disclosed

Pipeline

Target
GARP

ARGX-115, now known as ABBV-151, was designed as a SIMPLE Antibody® inhibitor of GARP-TGF-β1 and is being investigated by AbbVie for the treatment of cancer. ARGX-115 is designed to block GARP and to reactive the immune system against tumors.